MarkLevinMD

Oncology • Monsey, NY

Physician

Join to view full profile

Dr. Levin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Levin's full profile

Already have an account?

Office
6 Gel Ct
Monsey, NY 10952
Fax+1 845-426-0009
Is this information wrong?

Education & Training

Zucker School of Medicine at Hofstra/NorthwellFellowship, Hematology and Medical Oncology, 1987 - 1990
New York Downtown HospitalResidency, Internal Medicine, 1986 - 1987
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1984 - 1986
State University of New York Downstate Medical Center College of MedicineClass of 1984

Certifications & Licensure

NJ State Medical License 2001 - 2025
NY State Medical License 1986 - 2025
CT State Medical License 2011 - 2022
PA State Medical License 2020 - 2022
FL State Medical License 2016 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Biology, early diagnosis, prevention and management of early and advanced breast cancer.
Mark Levin> ;Drug News & Perspectives. 2005 Apr 1
1 citations
Multidisciplinary approach to breast cancer management.
Mark Levin> ;Drug News & Perspectives. 2004 Apr 1
14 citations
The promise of thalidomide: evolving indications.
Swati Joglekar, Mark Levin> ;Drugs of Today. 2004 Mar 1
2 citations
Breast cancer: issues in risk reduction, screening and surveillance, early identification and therapy planning.
Mark Levin> ;Drug News & Perspectives. 2003 Jul 1
Advances in colon cancer.
Mark Levin> ;Drug News & Perspectives. 2003 Jun 1
Gaucher disease: Genetics, diagnosis and management.
Mark Levin, Pleskova I, Pastores Gm> ;Drugs of Today. 2001 Apr 1
Chemotherapy Foundation Symposium XIX: Innovative cancer therapy for tomorrow.
Mark Levin> ;Drugs of Today. 2001 Dec 1
Recent advances in the field of platelet and bone marrow physiology and myeloproliferative and myelodysplastic diseases.
Mark Levin> ;Drugs of Today. 2001 Dec 1
Recent developments in antimutagenesis and anticarcinogenesis.
Mark Levin> ;Drugs of Today. 2002 Jul 1
3 citations
Direct-to-Consumer Advertising of Genetic Testing
Mark Levin> ;JAMA. 2003 Jan 1
6 citations
Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer.
Mark Levin, Sajani Durgam, Allan Novetsky> ;Cancer Investigation. 2002 Nov 27
Meeting report of the American Society of Preventive Oncology.
Mark Levin> ;Drugs of Today. 2001 Apr 1
5 citations
The role of taxanes in breast cancer treatment.
Mark Levin> ;Drugs of Today. 2001 Jan 1
Translocation (3;3) in a patient with thrombocytopenia and erythroid dysplasia.
Cecily J. Madahar, Mark Levin, Jyoti Roy, Maureen Conti> ;Cancer Genetics and Cytogenetics. 1996 Mar 1
41 citations
Relationship of Adriamycin Concentrations to the DNA Lesions Induced in Hypoxic and Euoxic L1210 Cells
Milan Potmesil, Stanley Kirschenbaum, Mervyn Israel, Mark Levin, Vinod K. Khetarpal, Robert Silber> ;Cancer Research. 1983 Aug 1
9 citations
In vivo effects of adriamycin or N-trifluoroacetyladriamycin-14-valerate on a mouse lymphoma.
Milan Potmesil, Mark Levin, Frank Traganos, Mervyn Israel, Zbigniew Darzynkiewicz, Vinod K. Khetarpal, Robert Silber> ;European Journal of Cancer & Clinical Oncology. 1983 Jan 1
21 citations
Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule
Robert J. Spiegel, Ronald H. Blum, Mark Levin, Carolina A. Pinto, J C Wernz, James L. Speyer, Kim S. Hoffman, Franco M. Muggia> ;Cancer Research. 1982 Jan 1
3 citations
Adriamycin Damage: In Vivo Repair by Lymphoma Cells
Milan Potmesil, Mark Levin, Anna Goldfeder, Robert Silber> ;Journal of the National Cancer Institute. 1981 Dec 1
49 citations
Protein-associated DNA breaks and DNA-protein cross-links caused by DNA nonbinding derivatives of adriamycin in L1210 cells.
Mark Levin, Robert Silber, Mervyn Israel, Anna Goldfeder, Vinod K. Khetarpal, Milan Potmesil> ;Cancer Research. 1981 Mar 1
158 citations
IMMUNOLOGIC STUDIES OF THE MAJOR NONIMMUNOGLOBULIN PROTEIN OF AMYLOID I. IDENTIFICATION AND PARTIAL CHARACTERIZATION OF A RELATED SERUM COMPONENT
Mark Levin, Mordechai Pras, Edward C. Franklin> ;The Journal of Experimental Medicine. 1973 Aug 1
27 citations
The partial amino acid sequence of the major low molecular weight component of two human amyloid fibrils.
Edward C. Franklin, Mordechai Pras, Mark Levin, Blas Frangione> ;FEBS Letters. 1972 Apr 15
Join now to see all

Press Mentions

De Blasio to Mandate Vaccinations for NYC Public Hospital Staff Amid COVID UptickJuly 20th, 2021
“What Exactly Did the Virus Do to All These People?” Reflections on Ted Nugent, Mel Q, Kelly Brogan, and John IoannidisJune 18th, 2021
'Life, Liberty & Levin' on COVID PandemicMay 25th, 2021
Join now to see all